Ladenburg initiated coverage of Marker Therapeutics with a Buy rating and $11 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
- Marker Therapeutics’ MT-601 Shows Promising Results
- Marker Therapeutics announces presentation on Phase 1 APOLLO study
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
- Marker Therapeutics Advances in Immuno-Oncology
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results